ArticleESC heart failure2026
Prognostic factors associated with fatal outcomes in COVID-19 vaccine-related myocarditis.
Article in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionVaccine-related myocarditis (VRM) has gained attention during the global roll-out of COVID-19 vaccines. COVID-19 VRM is usually non-fatal, but factors associated with fatal outcomes remain unclear. We aimed to characterize features associated with reported fatal outcomes using a pharmacovigilance database.
methodsWe retrospectively analysed COVID-19 VRM reports in the Japanese Adverse Drug Event Report database from 2021 to 2024. Reports were stratified into death and survival groups based on recorded outcome information. Logistic regression analyses identified factors associated with reported fatal outcomes.
results31 022 reports listed COVID-19 vaccines as suspected drug; 1041 reports included myocarditis [reporting odds ratio (ROR) 31.3, 95% CI 29.0-33.8]. The median time from vaccination to myocarditis onset was 2 (1-4) days, with most events occurring within 7 days. Among reports with VRM, men accounted for the majority (77.8%) and 68.6% were ≤39 years old. Outcome data were available for 863 reports, and death was recorded in 97 reports [11.2% (95% CI, 9.3%-13.5%)]. Reported fatal outcomes were more frequent in women, patients aged ≥70 years, those with delayed onset (≥8 days after COVID-19 vaccination), and those with ≥1 comorbidities. Multivariable logistic regression identified age ≥70 years as independently associated with reported fatal outcomes (OR 8.67, 95% CI 4.41-17.3; P < .001).
conclusionOlder age was associated with higher odds of reported fatal outcomes among VRM reports in JADER. Female sex, delayed onset, and comorbidities were more common among reports with fatal outcomes. These exploratory findings require validation in clinically adjudicated studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.